3349
COSMOS Pharmaceutical Corporation
コスモス薬品
- Industry
- Retail Trade
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Notes
- Stock adjustmentsJun 1, 2020 Stock split 1 share → 2 shares
- Stock adjustmentsSep 1, 2024 Stock split 1 share → 2 shares
Key metrics
Revenue(million JPY)
May 2021
726,424
May 2022
755,414
May 2023
827,697
May 2024
964,989
May 2025
1,011,390
Operating profit(million JPY)
May 2021
33,147
May 2022
29,796
May 2023
30,128
May 2024
31,501
May 2025
40,404
Operating profit margin(%)
May 2021
4.56
May 2022
3.94
May 2023
3.64
May 2024
3.26
May 2025
3.99
Profit before tax(million JPY)
May 2021
38,596
May 2022
33,048
May 2023
32,773
May 2024
33,719
May 2025
42,372
Profit(million JPY)
May 2021
27,156
May 2022
23,155
May 2023
23,797
May 2024
24,454
May 2025
30,978
Total assets(million JPY)
May 2021
341,318
May 2022
363,052
May 2023
420,967
May 2024
476,546
May 2025
524,755
Cash and cash equivalents(million JPY)
May 2021
55,108
May 2022
37,362
May 2023
45,928
May 2024
52,301
May 2025
57,038
Cash flows from operating activities(million JPY)
May 2021
27,875
May 2022
32,194
May 2023
54,434
May 2024
55,175
May 2025
52,467
Cash flows from investing activities(million JPY)
May 2021
-19,381
May 2022
-43,717
May 2023
-49,113
May 2024
-57,329
May 2025
-55,448
Cash flows from financing activities(million JPY)
May 2021
-5,507
May 2022
-6,222
May 2023
3,245
May 2024
8,527
May 2025
7,717
Return on equity(%)
May 2021
17.2
May 2022
12.8
May 2023
11.9
May 2024
11.1
May 2025
12.7
Equity ratio(%)
May 2021
50
May 2022
52.5
May 2023
50.1
May 2024
48.6
May 2025
49.1
Earnings per share(JPY per share)
May 2021
342.9
May 2022
292.38
May 2023
300.48
May 2024
308.61
May 2025
390.86
Net assets per share(JPY per share)
May 2021
2,153.815
May 2022
2,405.46
May 2023
2,665.13
May 2024
2,920.13
May 2025
3,248.45
Dividend per share(JPY per share)
May 2021
35
May 2022
40
May 2023
50
May 2024
60
May 2025
70
Payout ratio(%)
May 2021
10.21
May 2022
13.68
May 2023
16.64
May 2024
19.44
May 2025
17.91
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.